Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94,793Revenue $M52,317Net Margin (%)8.7Altman Z-Score2.1
Enterprise Value $M114,238EPS $5.5Operating Margin %10.2Piotroski F-Score6
P/E(ttm)20.7Beneish M-Score-2.6Pre-tax Margin (%)11.4Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %5.8Quick Ratio0.9Cash flow > EarningsY
Price/Sales1.85-y EBITDA Growth Rate %7.6Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow19.2y-y EBITDA Growth Rate %15.3ROA % (ttm)5.5Higher Current Ratio y-yN
Dividend Yield %2.5PEG3.0ROE % (ttm)18.3Less Shares Outstanding y-yY
Payout Ratio %46.0Shares Outstanding M827ROIC % (ttm)8.8Gross Margin Increase y-yY

Gurus Latest Trades with BAYRY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAYRYKen Fisher 2016-03-31 Add0.03%$103.65 - $124.84
($111.18)
$ 114.633%Add 2.63%4,833,445
BAYRYKen Fisher 2015-12-31 Reduce$122.36 - $135.71
($128.61)
$ 114.63-11%Reduce -0.07%4,709,574
BAYRYKen Fisher 2015-09-30 Add0.03%$127.13 - $151.47
($139.59)
$ 114.63-18%Add 2.22%4,712,759
BAYRYKen Fisher 2015-06-30 Add0.59%$139.35 - $155
($147.22)
$ 114.63-22%Add 83.74%4,610,296
BAYRYKen Fisher 2015-03-31 Add$130.2 - $155.97
($144.95)
$ 114.63-21%Add 0.63%2,509,075
BAYRYKen Fisher 2014-06-30 Add0.6%$126.84 - $144.81
($138.38)
$ 114.63-17%Add 750.48%2,302,369
BAYRYKen Fisher 2014-03-31 Add0.06%$128.3 - $142.7
($135.49)
$ 114.63-15%Add 217.05%270,713
BAYRYKen Fisher 2013-06-30 Add0.01%$101 - $112.75
($106.88)
$ 114.637%Add 34.62%84,456
BAYRYVanguard Health Care Fund 2012-09-30 Reduce-0.03%$68.01 - $88.62
($77.6)
$ 114.6348%Reduce -3.71%2,594,656
BAYRYKen Fisher 2012-09-30 Buy 0.02%$68.01 - $88.62
($77.14)
$ 114.6349%New holding72,838
BAYRYKen Fisher 2012-03-31 Sold Out -0.01%$0.04 - $75.15
($59.98)
$ 114.6391%Sold Out0
BAYRYKen Fisher 2011-09-30 Add$49.73 - $84.17
($66.88)
$ 114.6371%Add 24.27%46,440
BAYRYJohn Keeley 2009-06-30 Sold Out -0.01%$47.66 - $59.35
($52.77)
$ 114.63117%Sold Out0
BAYRYKen Fisher 2009-06-30 Sold Out $47.66 - $59.35
($52.77)
$ 114.63117%Sold Out0
BAYRYJohn Keeley 2009-03-31 Buy 0.01%$43.75 - $59.4
($52.7)
$ 114.63118%New holding6,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAYRY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAYRY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about BAYRY:

    News about BAYRY:

    Articles On GuruFocus.com
    Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
    Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
    UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
    Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 
    Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
    DuPont Eyeing Acquisition To Leverage Its Market Spread Apr 24 2015 
    Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
    Zoetis Will Benefit from Industry Trends Oct 07 2014 
    Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
    Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 

    More From Other Websites
    Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View Apr 27 2016
    Bayer AG downgraded by Credit Suisse Apr 27 2016
    Recent Drug Launches Buoy Bayer's Growth Apr 27 2016
    What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings? Apr 26 2016
    Bayer Beats Earnings Estimates, Gets Boost From Pharma Sales Apr 26 2016
    [$$] Bayer Posts 13% Jump in Net Profit Apr 26 2016
    Interim report for the first quarter of 2016: Bayer off to a successful start in 2016 Apr 26 2016
    Bayer Profit Beats Estimates as Newest Drugs Buoy Demand Apr 26 2016
    Ironwood to decide soon on a target disease for its next potential blockbuster Apr 25 2016
    Not intended for U.S. and UK Media -- Patent Term for Rivaroxaban Extended in US Apr 25 2016
    Prestigious award from the Bayer Science & Education Foundation: -- 2016 Otto Bayer Award goes to... Apr 25 2016
    Bayer showcases innovative approaches to drive sustainability in banana production Apr 21 2016
    Bayer deposits 10 million Covestro shares in Bayer Pension Trust e. V. Apr 21 2016
    Bayer and Hamburg University agree research collaboration: -- New digital solutions for sustainable... Apr 19 2016
    New Data Reaffirm Positive Benefit-Risk Balance of Bayer’s Xarelto® in Patients with Atrial... Apr 18 2016
    Investing in the future of agriculture: -- Bayer and Trendlines establish Ag Innovation Fund --... Apr 18 2016
    Bayer Barks, But Will It Bite? Apr 15 2016
    Latest innovation out of RTP? New Bayer wheat product Apr 13 2016
    Not intended for U.S. and UK Media - 107th Annual Meeting of American Association for Cancer... Apr 13 2016
    Bayer's New Chief Plans to Bolster Animal Unit With Deals Apr 12 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)